Clomiphene Citrate (Clomid) - SERM for Fertility & HPTA Recovery — Anabolic Steroids
SERM that stimulates gonadotropin release (LH/FSH), FDA-approved for female ovulatory dysfunction, used off-label for male hypogonadism and as a cornerstone of post-cycle therapy after AAS cycles.
Overview
Clomiphene citrate (Clomid) is a non-steroidal SERM composed of two geometric isomers: enclomiphene (trans-isomer, predominantly anti-estrogenic) and zuclomiphene (cis-isomer, predominantly estrogenic). FDA-approved since 1967 for ovulatory dysfunction in women, it remains first-line therapy for anovulatory infertility. In males, clomiphene is increasingly used off-label as a TRT alternative for hypogonadism, with meta-analyses demonstrating 2-3x increases in total testosterone while preserving fertility (unlike exogenous testosterone which suppresses spermatogenesis). A systematic review of 1,482 hypogonadal men showed mean testosterone increase from 228 ng/dL to 612 ng/dL (PMID: 25561023). The compound blocks estrogen receptors at the hypothalamus, disinhibiting GnRH pulsatility and increasing LH/FSH release. In bodybuilding, clomiphene is a staple PCT compound used after AAS cycles to accelerate HPTA recovery. Enclomiphene (the isolated trans-isomer) is under development as a dedicated male hypogonadism treatment. PMID: 25561023, 28415879, 22458540.
Indications
- Ovulatory dysfunction and anovulatory infertility in women (FDA-approved; first-line per ASRM guidelines)
- Male hypogonadism as TRT alternative preserving fertility (off-label; growing evidence base)
- Post-cycle therapy (PCT) after anabolic steroid cycles for HPTA recovery (off-label, bodybuilding use)
- Unexplained male infertility with low-normal testosterone (off-label)
- Diagnostic test for hypothalamic-pituitary reserve (clomiphene stimulation test)
Mechanism of Action
Clomiphene competitively blocks estrogen receptors in the hypothalamus, preventing estradiol from exerting negative feedback on GnRH pulse generator neurons
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Clomiphene Citrate (Clomid) | 50 mg | Days 3-7 or 5-9 of menstrual cycle | Standard ovulation induction protocol; 5-day course per cycle |
| Clomiphene Citrate | 100 mg | Days 3-7 or 5-9 of menstrual cycle | Dose escalation if no ovulation at 50mg; maximum 3-6 cycles |
| Clomiphene Citrate | 25-50 mg | Once daily (continuous) | Male hypogonadism TRT alternative; continuous dosing to maintain testosterone levels |
| Clomiphene Citrate | 50 mg | Once daily for 4 weeks (PCT) | Standard PCT dose; may combine with tamoxifen; begin after steroid clearance |
| Clomiphene Citrate | 100 mg/day tapering to 50 mg/day | 2 weeks at 100mg then 2 weeks at 50mg | Aggressive PCT protocol; 4-week total duration |
Evidence Grade
GRADE A
Safety & Contraindications
- Ovarian hyperstimulation syndrome (OHSS) in women: abdominal pain, bloating, nausea; can be severe with ascites and pleural effusion
- Multiple gestation risk: 5-8% twin pregnancy rate (vs 1% baseline); rare higher-order multiples
- Visual disturbances (blurred vision, scotomata, flashes) in 1.5-2% of patients; discontinue immediately if occur
- Hot flashes (10%), mood swings, and emotional lability are common
- In males, long-term zuclomiphene accumulation (estrogenic isomer) may cause gynecomastia; enclomiphene monotherapy under development to address this
- Hepatotoxicity rare but reported; monitor LFTs in long-term use